The Health Service Executive (HSE) in Ireland has confirmed nine cases of invasive meningococcal disease (IMD) caused by the B strain so far in 2026. The public health agency stated there is no evidence of an increase in case numbers compared to previous years and no epidemiological link to a separate outbreak in Kent, England.
In the United Kingdom, health authorities have been responding to a localized outbreak of meningococcal disease, primarily among university students in Kent. This outbreak has involved multiple strains, including MenB, and has resulted in tragic fatalities. The UK Health Security Agency (UKHSA) has led a vaccination campaign in response.
The HSE emphasized that the situation in Ireland remains stable and within expected seasonal patterns. Meningitis B is a notifiable disease in Ireland, and cases occur every year. Public health advice focuses on recognizing the symptoms, which can include fever, headache, stiff neck, and a rash that does not fade under pressure.
Vaccination is a key preventative measure. The MenB vaccine (Bexsero) is part of the Irish childhood immunization schedule, offered to infants at 2, 4, and 12 months. The HSE continues to monitor the situation closely and urges anyone with concerns about symptoms to seek immediate medical attention.
